Liver Transplant Program

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. Non-Invasive Method of Diagnosing Rejection for Liver Transplant Patients

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

   The purpose of this study is to validate the use of a RNAseq-based peripheral blood assay in liver transplant recipients when correlated to liver biopsy results.

2. A Study to Learn More About the Chemicals Produced by Cells Involved in Liver Regeneration (regrowth) After Living Liver Donation

   Rochester, Minn.

   The purpose of this study is to characterize the readily available (circulating in peripheral blood) mediators of cell proliferation in individuals undergoing living liver donation.

3. A Study of Donated Alloantigen Reactive Regulatory T Cells for Reducing or Discontinuing Immune System Suppression in Liver Transplant Patients

   Rochester, Minn.

   This research study is for liver transplant recipients and their respective living donors. The purpose of this study is to see if it is safe for liver recipients to receive one dose of donor reactive T regulatory cells (Tregs), and if the Tregs allows a liver recipient to take less, or completely stop medications normally taken after receiving an organ transplant.

4. A Study Looking at the Impact of Gabriel House of Care (a Hospital Hospitality House, HHH) on the Quality of Life and Mood of Liver Transplant Patients

   Jacksonville, Fla.

   The aim of this study is to measure the differences in quality of life and mood of liver transplant recipients in the immediate month post- transplant staying at the Gabriel House of Care staying at a hotel, apartment or rental property. 

5. Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   The primary objective of this study is to evaluate whether obeticholic acid (OCA; INT-747) can lead to histological improvement in fibrosis with no worsening of NASH in adults with compensated cirrhosis due to NASH.

6. A Study to Confirm the Effectiveness and Safety of Terlipressin for Treatment of Hepatorenal Syndrome Type 1

   Rochester, Minn., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to confirm the effectiveness and safety of  terlipressin in the treatment of adult patients with hepatorenal syndrome (HRS) type 1.

7. A Study to Better Understand Why Patients Gain Weight After Undergoing Liver Transplantation

   Rochester, Minn.

   The purpose of this study is to understanding the mechanisms of weight gain in patients following liver transplantation, action, and indicate approaches to prevent weight gain.

8. Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   The purpose of this multicenter, double-blind, randomized, placebo-controlled study is to evaluate the safety and efficacy of emricasan in improving event-free survival based on a composite clinical endpoint (where all-cause mortality, new decompensation events, and MELD score progression are events) in subjects with decompensated NASH cirrhosis.

9. Study to Evaluate the Safety and Effectiveness of BMS-986036 in Adults with Nonalcoholic Steatophepatitis (NASH) and Compensated Liver Fibrosis

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to evaluate the safety and effectiveness of BMS-986036 in adults with nonalcoholic steatophepatitis (NASH) and compensated liver fibrosis.

10. A Study of Using Ultrasound to Evaluate Post-Transplant Acute Liver Rejection

    Rochester, Minn.

    Liver biopsy is routinely performed at day 7 after liver transplant at Mayo to evaluate acute liver rejection.The purpose of this study is to assess the feasibility of a non-invasive evaluation of acute liver rejection by using ultrasound measurements.